Alcon Inc. (ALC) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Alcon Inc. (ALC) Healthcare & Pipeline Overview

Alcon Inc., a global leader in eye care, provides a comprehensive portfolio of surgical and vision care products. With a focus on innovation and patient outcomes, Alcon serves eye care professionals and patients worldwide, addressing needs from cataract surgery to contact lenses and ocular health.

What Is the Investment Thesis for ALC?

Alcon presents a notable research candidate within the growing eye care market. The company's diverse product portfolio across surgical and vision care segments provides resilience and multiple avenues for growth. With an aging global population and increasing prevalence of eye-related conditions, demand for Alcon's products is expected to rise. A P/E ratio of 39.61 reflects investor confidence, while a 0.57% dividend yield offers a modest income stream. Key catalysts include continued innovation in IOL technology and expansion in emerging markets. Potential risks include competition from established players and the impact of healthcare regulations.

Based on FMP financials and quantitative analysis

ALC Key Highlights

Market Cap of $32.5B reflects Alcon's significant presence in the eye care industry.

• Profit Margin of 7.7% indicates solid profitability and operational efficiency.
• Gross Margin of 54.9% demonstrates Alcon's ability to maintain pricing power and manage costs effectively.
• Beta of 0.70 suggests lower volatility compared to the overall market, making it a relatively stable investment.
• Dividend Yield of 0.57% provides a small but consistent return to shareholders.

Who Are ALC's Competitors?

ALC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ALC's Key Strengths?

Strong brand reputation and global presence.

• Diverse product portfolio across surgical and vision care.
• Extensive research and development capabilities.
• Established relationships with eye care professionals.

What Are ALC's Weaknesses?

Exposure to competition from established players.

• Dependence on innovation for growth.
• Potential impact of healthcare regulations.
• Currency exchange rate fluctuations.

What Could Drive ALC Stock Higher?

Launch of new advanced technology IOLs designed to improve visual outcomes for cataract patients.

• Expansion of Alcon's presence in emerging markets, particularly in Asia and Latin America.
• Continued investment in research and development of innovative eye care products.
• Strategic partnerships and acquisitions to expand product portfolio and geographic reach.

What Are the Key Risks for ALC?

Rich valuation — a P/E of 39.61 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Increased competition from established players and new entrants in the eye care market.
• Impact of healthcare regulations and reimbursement policies on Alcon's profitability.
• Product liability claims related to Alcon's surgical and vision care products.
• Currency exchange rate fluctuations affecting Alcon's financial results.
• Technological obsolescence and the need for continuous innovation.

What Are the Growth Opportunities for ALC?

• Expansion in Emerging Markets: Alcon has a significant opportunity to expand its presence in emerging markets, particularly in Asia and Latin America. These regions have a large and growing population with increasing awareness of eye care needs. By establishing strategic partnerships and tailoring its product offerings to local market demands, Alcon can tap into a substantial new customer base. This expansion can drive revenue growth and increase Alcon's global market share in the coming years.
• Innovation in Intraocular Lenses (IOLs): Alcon's continued investment in research and development of advanced technology IOLs presents a significant growth opportunity. As the demand for presbyopia-correcting and astigmatism-correcting IOLs increases, Alcon can capitalize on this trend by launching innovative products that offer improved visual outcomes for patients undergoing cataract surgery. This will strengthen Alcon's competitive position and drive revenue growth in the surgical segment.
• Growth in Ocular Health Products: The increasing prevalence of dry eye disease and other ocular surface conditions creates a significant growth opportunity for Alcon's Vision Care segment. By developing and marketing innovative ocular health products, such as advanced artificial tears and prescription medications, Alcon can address the unmet needs of patients suffering from these conditions. This will expand Alcon's customer base and drive revenue growth in the vision care segment.
• Strategic Acquisitions and Partnerships: Alcon can pursue strategic acquisitions and partnerships to expand its product portfolio and geographic reach. By acquiring companies with complementary technologies or market access, Alcon can accelerate its growth and strengthen its competitive position. This strategy can also help Alcon enter new therapeutic areas and diversify its revenue streams.
• Digitalization of Eye Care: Alcon can leverage digital technologies to enhance its product offerings and improve patient outcomes. This includes developing telemedicine platforms for remote eye exams, using artificial intelligence to improve diagnostic accuracy, and creating personalized treatment plans based on patient data. By embracing digital innovation, Alcon can differentiate itself from competitors and drive growth in the evolving eye care landscape.

What Are ALC's Competitive Advantages?

• Strong brand reputation and recognition in the eye care industry.
• Extensive product portfolio across surgical and vision care segments.
• Global distribution network and established relationships with eye care professionals.
• Significant investment in research and development, leading to innovative products.
• Patents and intellectual property protecting key products and technologies.

What Does ALC Do?

Founded in 1945 in Fort Worth, Texas, as a small pharmacy, Alcon Inc. has evolved into a global leader in eye care. Initially focused on manufacturing sterile ophthalmic solutions, Alcon expanded its product line through research and development, strategic acquisitions, and partnerships. In 2001, the company changed its name from Alcon Universal S.A. to Alcon Inc. Alcon's two main business segments are Surgical and Vision Care. The Surgical segment offers equipment, instrumentation, intraocular lenses (IOLs), and consumables for cataract, refractive, and vitreoretinal surgery. Key products include the Centurion Vision System, LenSx femtosecond laser, and a range of AcrySof IOLs. The Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses, as well as ocular health products for dry eye, glaucoma, and contact lens care. Brands include TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, and Opti-Free. Headquartered in Geneva, Switzerland, Alcon serves eye care professionals and patients in over 140 countries.

What Products and Services Does ALC Offer?

• Researches and develops eye care products.
• Manufactures surgical equipment and instruments for eye procedures.
• Produces intraocular lenses (IOLs) for cataract surgery.
• Offers a range of contact lenses, including daily disposables and reusable options.
• Provides ocular health products for dry eye, glaucoma, and allergies.
• Distributes and sells its products to eye care professionals and patients worldwide.

How Does ALC Make Money?

• Develops and manufactures eye care products.
• Sells products through direct sales force and distributors.
• Generates revenue from surgical equipment, IOLs, contact lenses, and ocular health products.
• Invests in research and development to innovate new products and technologies.

What Industry Does ALC Operate In?

The medical instruments and supplies industry is driven by technological advancements, an aging population, and increasing healthcare spending. Alcon operates in a competitive landscape, facing rivals such as Becton, Dickinson and Company (BDX) and Cardinal Health, Inc. (CAH). The global market for eye care products is projected to grow steadily, fueled by rising rates of myopia, cataracts, and other vision impairments. Alcon's focus on innovation and its established brand reputation position it favorably to capture a significant share of this expanding market.

Who Are ALC's Key Customers?

• Eye care professionals (ophthalmologists and optometrists)
• Hospitals and surgical centers
• Patients with vision impairments
• Contact lens wearers

Wall Street analysts project Alcon Inc. revenue of about $11.08B for fiscal 2026, with EPS near $3.49. The estimate reflects 15 contributing analysts.

Alcon Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 4.4% above estimates on average.

Alcon Inc.'s Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.68 places it in the grey zone, a middle ground that warrants monitoring.

Return on equity for Alcon Inc. stands at 3.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.6%, showing how much profit it generates from its asset base. ALC trades at a trailing price-to-earnings ratio of 39.61, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 5.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.20 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.5%, the inverse of the P/E and a quick read on earnings relative to price.

Alcon Inc. (ALC) Valuation Context

Valued at $32.5B, ALC is classified as a large-cap stock. Analyst price targets span from $35.00 to $85.00, with a consensus of $73.43. At the current price of $66.55, that implies approximately 10% upside potential. Relative to its peer group, ALC's quantitative score of 76/100 is roughly in line with the peer average of 77/100.

ALC Revenue & Earnings Trend

In Jun 2026, ALC generated $2.82B in top-line revenue, marking a sequential increase of 6.4%. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare.

Company Profile

Alcon Inc. operates in the Medical - Specialties industry within the Healthcare sector. It is headquartered in Geneva, CH. The company is led by CEO David J. Endicott. ALC has traded publicly since 2019.

ALC Financials

ALC Latest News

ALC Analyst Consensus

ALC MoonshotScore

Common Questions About ALC (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources